Affibody, ACELYRIN, and Inmagene Bio Announce Positive Results from Global Phase 2 Trial of Izokibep in Patients with Psoriatic Arthritis
Solna, Sweden, Los Angeles, USA, and Shanghai, China, May 3, 2022 – ACELYRIN, INC., Affibody AB, and Inmagene Biopharmaceuticals Co., Ltd., today announced that a 16-week, global, Phase 2 clinical trial of izokibep in 135 patients with psoriatic arthritis (PsA) met its primary endpoint of ACR50. Izokibep also achieved secondary endpoints, including PASI response, enthesitis LEEDs improvement, and quality of life improvement on a clinically validated PsA-specific quality of life instrument, the Psoriatic Impact of Disease (PsAID) questionnaire.The randomized double-blind, placebo-controlled,